MegaRobo Technologies has raised nearly $200 million in new funding led by the Oman Investment Authority, with new investor CMB International joining returning backers Asia Investment Capital, Granite Asia and Sinovation Ventures. The round, announced November 18, 2026, pushes the China-based company's total funding past $600 million across multiple rounds. MegaRobo builds what it calls "intelligence infrastructure for the physical world" — robotic lab systems paired with AI software that design, run and learn from real experiments without constant human supervision.
What is MegaRobo's money actually buying?
The company says the new capital will fund core technology development, global expansion of its AI-for-Science business, and infrastructure that lets AI operate reliably in messy, unstructured physical settings. That is a harder problem than it sounds: a model can generate a hypothesis in seconds, but testing it still requires pipetting, mixing, incubating and measuring in a physical lab.
MegaRobo's answer is to put robotic arms and automated scientific instruments directly under AI control, closing the loop between a model's prediction and a lab's physical result. Its Megalaxy Lab platform already serves more than 200 customers running programmable experiments remotely, and the company counts more than 500 total customers across pharmaceutical, biotech and research institutions, according to PR Newswire.
The company also recently launched Poreva Open, a global AI protein-design challenge that offers wet-lab validation for more than 10,000 submitted protein sequences. That program is a showcase for the core pitch: anyone can propose a protein design, and MegaRobo's robotic labs will actually synthesize and test it, rather than leaving the claim unverified in simulation.
Why would Oman's sovereign fund back a Chinese lab-robotics company?
Sovereign wealth funds have been diversifying into deep-tech bets that sit outside oil and gas, and AI-driven physical infrastructure is one of the few categories where early capital can still buy a meaningful stake before prices run up further. The Oman Investment Authority's decision to lead a round for a Chinese AI-robotics company, rather than a US or European one, also reflects how capital for physical AI has become genuinely global, with Gulf money flowing into Asian hardware and automation plays alongside the data-center deals it is better known for.
The return of three existing investors — Asia Investment Capital, Granite Asia and Sinovation Ventures — alongside new investor CMB International suggests the company's earlier backers are doubling down rather than exiting, a signal that MegaRobo's roughly $600 million in cumulative funding is being treated as a platform bet rather than a one-off.
How does this compare to other AI-for-science or lab-automation companies?
MegaRobo's pitch sits between two existing categories: automated lab-equipment makers that sell hardware without AI decision-making, and AI drug-discovery companies, like Isomorphic Labs, that design molecules computationally but still hand off physical testing to someone else. MegaRobo is trying to own both ends — the AI that proposes an experiment and the robots that run it — which is a more capital-intensive bet but one that removes a human bottleneck between hypothesis and result.
That full-stack approach is also why MegaRobo's funding has scaled into the hundreds of millions rather than staying at a typical biotech-tools round size: building and maintaining robotic lab infrastructure across hundreds of customer sites costs far more than shipping software alone.
What should investors and competitors watch next?
The clearest signal to track is whether MegaRobo's AI-for-Science business expands meaningfully outside China, since the company explicitly named global expansion as a use of the new capital. A second signal is how many of the 10,000-plus protein designs submitted to Poreva Open actually get validated and published, which would be concrete proof the automated-lab loop works at scale rather than in curated demos.